{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:33:46Z","timestamp":1790094826887,"version":"4.0.1"},"reference-count":67,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,18]],"date-time":"2013-07-18T00:00:00Z","timestamp":1374105600000},"content-version":"vor","delay-in-days":3334,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2004,6]]},"DOI":"10.1016\/j.rmed.2003.12.012","type":"journal-article","created":{"date-parts":[[2004,4,2]],"date-time":"2004-04-02T05:15:22Z","timestamp":1080882922000},"page":"495-503","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":75,"title":["PDE4 inhibitors in COPD\u2014a more selective approach to treatment"],"prefix":"10.1016","volume":"98","author":[{"given":"Antonio Maurizio","family":"Vignola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2003.12.012_BIB1","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S1471-4914(01)02156-6","article-title":"Cilomilast","volume":"7","author":"Giembycz","year":"2001","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.rmed.2003.12.012_BIB2","unstructured":"World Health Organization. The world health report. 1997. Available at: http:\/\/www.who.int\/whr2001\/2001\/archives\/1997\/index.htm"},{"key":"10.1016\/j.rmed.2003.12.012_BIB3","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1517\/13543784.10.7.1361","article-title":"Cilomilast","volume":"10","author":"Giembycz","year":"2001","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.rmed.2003.12.012_BIB4","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(96)07492-2","article-title":"Alternative projections of mortality and disability by cause 1990\u20132020","volume":"349","author":"Murray","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.rmed.2003.12.012_BIB5","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1126\/science.274.5288.740","article-title":"Evidence-based health policy\u2014lessons from the Global Burden of Disease Study","volume":"274","author":"Murray","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.rmed.2003.12.012_BIB6","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1164\/ajrccm.163.5.2101039","article-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI\/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary","volume":"163","author":"Pauwels","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2003.12.012_BIB7","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI\/WHO Workshop Report 2001 (Updated 2003). 2003."},{"key":"10.1016\/j.rmed.2003.12.012_BIB8","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1183\/09031936.03.00405703","article-title":"Systemic effects of chronic obstructive pulmonary disease","volume":"21","author":"Agusti","year":"2003","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2003.12.012_BIB9","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1056\/NEJM200007273430407","article-title":"Chronic obstructive pulmonary disease","volume":"343","author":"Barnes","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmed.2003.12.012_BIB10","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1053\/rmed.2002.1334","article-title":"The costs of exacerbations in chronic obstructive pulmonary disease (COPD)","volume":"96","author":"Andersson","year":"2002","journal-title":"Respir Med"},{"key":"10.1016\/j.rmed.2003.12.012_BIB11","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1164\/ajrccm.157.5.9709032","article-title":"Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease","volume":"157","author":"Seemungal","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2003.12.012_BIB12","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S1367-5931(00)00105-8","article-title":"Chronic obstructive pulmonary disease","volume":"4","author":"Hay","year":"2000","journal-title":"Curr Opin Chem Biol"},{"key":"10.1016\/j.rmed.2003.12.012_BIB13","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/00063198-200003000-00014","article-title":"New phosphodiesterase inhibitors as therapeutics for the treatment of chronic lung disease","volume":"6","author":"Barnette","year":"2000","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.rmed.2003.12.012_BIB14","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1006\/pupt.1999.0181","article-title":"Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD","volume":"12","author":"Torphy","year":"1999","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.rmed.2003.12.012_BIB15","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1164\/ajrccm.164.supplement_2.2106061","article-title":"Remodeling in asthma and chronic obstructive lung disease","volume":"164","author":"Jeffery","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2003.12.012_BIB16","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1164\/ajrccm.163.6.2009116","article-title":"Cellular and structural bases of chronic obstructive pulmonary disease","volume":"163","author":"Saetta","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2003.12.012_BIB17","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/nrm911","article-title":"Cyclic nucleotide research\u2014still expanding after half a century","volume":"3","author":"Beavo","year":"2002","journal-title":"Natl Rev Mol Cell Biol"},{"key":"10.1016\/j.rmed.2003.12.012_BIB18","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1164\/ajrccm.157.2.9708012","article-title":"Phosphodiesterase isozymes","volume":"157","author":"Torphy","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2003.12.012_BIB19","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1067\/mai.2001.119555","article-title":"Cyclic nucleotide phosphodiesterases","volume":"108","author":"Essayan","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmed.2003.12.012_BIB20","doi-asserted-by":"crossref","first-page":"192S","DOI":"10.1378\/chest.121.5_suppl.192S","article-title":"Phosphodiesterase 4 inhibitors for the treatment of COPD","volume":"121","author":"Sturton","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2003.12.012_BIB21","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0165-6147(97)90613-1","article-title":"Phosphodiesterase (PDE)4 inhibitors","volume":"18","author":"Teixeira","year":"1997","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.rmed.2003.12.012_BIB22","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S0022-3565(24)37221-0","article-title":"SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor","volume":"284","author":"Barnette","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"issue":"Suppl 3","key":"10.1016\/j.rmed.2003.12.012_BIB23","first-page":"24","article-title":"The role of theophylline and phosphodiesterase4 isoenzyme inhibitors as anti-inflammatory drugs","volume":"28","author":"Spina","year":"1998","journal-title":"Clin Exp Allergy"},{"issue":"Suppl 3","key":"10.1016\/j.rmed.2003.12.012_BIB24","first-page":"53","article-title":"Therapeutic activities of theophylline in chronic obstructive pulmonary disease","volume":"28","author":"Peleman","year":"1998","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.rmed.2003.12.012_BIB25","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1164\/rccm.2105106","article-title":"Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in chronic obstructive pulmonary disease","volume":"165","author":"Culpitt","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2003.12.012_BIB26","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1164\/rccm.200210-1142PP","article-title":"Theophylline","volume":"167","author":"Barnes","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2003.12.012_BIB27","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1136\/thx.46.7.512","article-title":"Phosphodiesterase inhibitors","volume":"46","author":"Torphy","year":"1991","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2003.12.012_BIB28","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1136\/thx.51.6.647","article-title":"Phosphodiesterase inhibitors","volume":"51","author":"Dent","year":"1996","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2003.12.012_BIB29","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/0091-6749(86)90044-8","article-title":"Relationships between adenosine, cyclic nucleotides, and xanthines in asthma","volume":"78","author":"Church","year":"1986","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmed.2003.12.012_BIB30","doi-asserted-by":"crossref","first-page":"8921","DOI":"10.1073\/pnas.132556899","article-title":"A molecular mechanism of action of theophylline","volume":"99","author":"Ito","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.rmed.2003.12.012_BIB31","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1365-2222.1992.tb03095.x","article-title":"Prospects for selective cyclic nucleotide phosphodiesterase inhibitors in the treatment of bronchial asthma","volume":"22","author":"Giembycz","year":"1992","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.rmed.2003.12.012_BIB32","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S0022-3565(24)29538-0","article-title":"In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor","volume":"297","author":"Bundschuh","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.rmed.2003.12.012_BIB33","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1006\/pupt.1999.0182","article-title":"Therapeutic potential of selective PDE inhibitors in asthma","volume":"12","author":"Schudt","year":"1999","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.rmed.2003.12.012_BIB34","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S0022-3565(24)37892-9","article-title":"Antiasthmatic activity of the second-generation phosphodiesterase 4 (PDE4) inhibitor SB 207499 (Ariflo) in the guinea pig","volume":"287","author":"Underwood","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.rmed.2003.12.012_BIB35","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0022-3565(24)29537-9","article-title":"Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro","volume":"297","author":"Hatzelmann","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.rmed.2003.12.012_BIB36","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0014-2999(02)01810-1","article-title":"Effects of the phosphodiesterase 4 inhibitors SB 207499 and AWD 12-281 on the inflammatory reaction in a model of allergic dermatitis","volume":"446","author":"Baumer","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.rmed.2003.12.012_BIB37","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1136\/thorax.58.7.573","article-title":"Effect of cilomilast (Ariflo) on TNF-alpha, IL-8, and GM-CSF release by airway cells of patients with COPD","volume":"58","author":"Profita","year":"2003","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2003.12.012_BIB38","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1165\/rcmb.4818","article-title":"Phosphodiesterase 4 inhibitor cilomilast inhibits fibroblast-mediated collagen gel degradation induced by tumor necrosis factor-alpha and neutrophil elastase","volume":"27","author":"Kohyama","year":"2002","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.rmed.2003.12.012_BIB39","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1165\/ajrcmb.26.6.4743","article-title":"PDE4 inhibitors attenuate fibroblast chemotaxis and contraction of native collagen gels","volume":"26","author":"Kohyama","year":"2002","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.rmed.2003.12.012_BIB40","doi-asserted-by":"crossref","unstructured":"Gamble E, Grootendorst DC, Brightling CE, et al. Anti-inflammatory effects of the phosphodiesterase 4 inhibitor cilomilast (Ariflo) in COPD. Am J Respir Crit Care Med 2003.","DOI":"10.1164\/rccm.200212-1490OC"},{"key":"10.1016\/j.rmed.2003.12.012_BIB41","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1038\/sj.bjp.0701723","article-title":"Effect of PDE4 inhibitors on zymosan-induced IL-8 release from human neutrophils","volume":"123","author":"Au","year":"1998","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.rmed.2003.12.012_BIB42","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1136\/thx.54.8.730","article-title":"Long acting beta-2 agonists and theophylline in stable chronic obstructive pulmonary disease","volume":"54","author":"Cazzola","year":"1999","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2003.12.012_BIB43","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/j.1875-9114.1983.tb04531.x","article-title":"Theophylline. A state of the art review","volume":"3","author":"Hendeles","year":"1983","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.rmed.2003.12.012_BIB44","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1177\/002580249103100306","article-title":"The effect of salbutamol on breath alcohol testing in asthmatics","volume":"31","author":"Gomm","year":"1991","journal-title":"Med Sci Law"},{"key":"10.1016\/j.rmed.2003.12.012_BIB45","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/0736-4679(93)90244-2","article-title":"Theophylline toxicity","volume":"11","author":"Cooling","year":"1993","journal-title":"J Emerg Med"},{"key":"10.1016\/j.rmed.2003.12.012_BIB46","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2165\/00003088-199936060-00004","article-title":"Drug interactions with tobacco smoking. An update","volume":"36","author":"Zevin","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.rmed.2003.12.012_BIB47","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2165\/00002512-200320010-00005","article-title":"Differential pharmacokinetics of theophylline in elderly patients","volume":"20","author":"Ohnishi","year":"2003","journal-title":"Drugs Aging"},{"key":"10.1016\/j.rmed.2003.12.012_BIB48","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1136\/bmj.297.6662.1506","article-title":"Dose response relation to oral theophylline in severe chronic obstructive airways disease","volume":"297","author":"Chrystyn","year":"1988","journal-title":"BMJ"},{"key":"10.1016\/j.rmed.2003.12.012_BIB49","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1177\/009127000104100904","article-title":"An overview of the pharmacokinetics of cilomilast (Ariflo), a new, orally active phosphodiesterase 4 inhibitor, in healthy young and elderly volunteers","volume":"41","author":"Zussman","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.rmed.2003.12.012_BIB50","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1358\/mf.2000.22.4.584459","article-title":"A review of clinical use of theophylline in acute asthma","volume":"22","author":"Ohnishi","year":"2000","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"10.1016\/j.rmed.2003.12.012_BIB51","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/0091-6749(86)90054-0","article-title":"Therapeutic consequences of drug interactions with theophylline pharmacokinetics","volume":"78","author":"Jonkman","year":"1986","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmed.2003.12.012_BIB52","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2165\/00003088-198409040-00002","article-title":"Pharmacokinetic drug interactions with theophylline","volume":"9","author":"Jonkman","year":"1984","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.rmed.2003.12.012_BIB53","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1592\/phco.21.7.653.34569","article-title":"Bioavailability of the oral selective phosphodiesterase 4 inhibitor cilomilast","volume":"21","author":"Zussman","year":"2001","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.rmed.2003.12.012_BIB54","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/00325481.1992.11701272","article-title":"Drug treatment of COPD. Controversies about agents and how to deliver them","volume":"91","author":"Simon","year":"1992","journal-title":"Postgrad Med"},{"key":"10.1016\/j.rmed.2003.12.012_BIB55","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0140-6736(01)05481-2","article-title":"Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease","volume":"358","author":"Compton","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.rmed.2003.12.012_BIB56","unstructured":"Edelson JD, Compton C, Nieman R, et al. Cilomilast (Ariflo) 15mg BID safety in a 6-month clinical trial program. Am J Respir Crit Care Med 2001;163 (Suppl):A771."},{"key":"10.1016\/j.rmed.2003.12.012_BIB57","unstructured":"Edelson JD, Compton C, Nieman R, et al. Cilomilast (Ariflo), a potent, selective inhibitor of phosphodiesterase 4, improves lung function in COPD patients: results of a 6-month trial. Am J Respir Crit Care Med 2001;163 (Suppl):A277."},{"key":"10.1016\/j.rmed.2003.12.012_BIB58","unstructured":"Zhu J, Anderson K, Vleisides T, et al. The positive effect of cilomilast on lung function in patients with chronic obstructive pulmonary disease (COPD) is independent of patient smoking status. Eur Respir J 2002;20 (Suppl 38):620s."},{"key":"10.1016\/j.rmed.2003.12.012_BIB59","unstructured":"Leitchl S, Syed J, Bredenbroker D, et al. Efficacy of once-daily roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;165 (Suppl):A229."},{"key":"10.1016\/j.rmed.2003.12.012_BIB60","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1378\/chest.99.6.1415","article-title":"The arrhythmogenicity of theophylline. A multivariate analysis of clinical determinants","volume":"99","author":"Bittar","year":"1991","journal-title":"Chest"},{"issue":"Suppl","key":"10.1016\/j.rmed.2003.12.012_BIB61","first-page":"A595","article-title":"Safety of once-daily roflumilast, a new orally active, selective phosphodiesterase 4 inhibitor, in patients with COPD","volume":"165","author":"Bredenbroker","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl 38","key":"10.1016\/j.rmed.2003.12.012_BIB62","first-page":"P743","article-title":"Patients with severe renal impairment do not require dose adjustment of roflumilast","volume":"20","author":"Drollman","year":"2002","journal-title":"Eur Respir J"},{"issue":"Suppl","key":"10.1016\/j.rmed.2003.12.012_BIB63","first-page":"A594","article-title":"Pharmacokinetics of roflumilast and its active metabolite roflumilast-N-oxide is not influenced by smoking","volume":"165","author":"H\u00fcnnemeyer","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl 38","key":"10.1016\/j.rmed.2003.12.012_BIB64","first-page":"P744","article-title":"Pharmacokinetics of roflumilast and its active metabolite roflumilast N-oxide in middle aged and young subjects","volume":"20","author":"Manegold","year":"2002","journal-title":"Eur Respir J"},{"issue":"Suppl","key":"10.1016\/j.rmed.2003.12.012_BIB65","first-page":"A594","article-title":"Roflumilast and its active metabolite, roflumilast N-oxide, do not interact with inhaled salbutamol","volume":"165","author":"Weimar","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2003.12.012_BIB66","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/cpt1976195part1546","article-title":"Effect of smoking on theophylline disposition","volume":"19","author":"Hunt","year":"1976","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.rmed.2003.12.012_BIB67","doi-asserted-by":"crossref","first-page":"103S","DOI":"10.1378\/chest.88.2_Supplement.103S","article-title":"Update on the pharmacodynamics and pharmacokinetics of theophylline","volume":"88","author":"Hendeles","year":"1985","journal-title":"Chest"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611103004542?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611103004542?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T10:10:17Z","timestamp":1760609417000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611103004542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":67,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["S0954611103004542"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2003.12.012","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2004,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PDE4 inhibitors in COPD\u2014a more selective approach to treatment","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2003.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}